Case Study: How Do You Manage First Relapse Multiple Myeloma Following Upfront ASCT and Lenalidomide Maintenance?
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Upfront ASCT and Lenalidomide Maintenance?
Multiple Myeloma At First Relapse: Is My Patient Refractory to Lenalidomide?
Multiple Myeloma At First Relapse: Is My Patient Refractory to Lenalidomide?
Choosing and Sequencing Regimens in Relapsed Multiple Myeloma
Choosing and Sequencing Regimens in Relapsed Multiple Myeloma
Monoclonal Antibody-Based Regimens for Early Relapse Multiple Myeloma
Monoclonal Antibody-Based Regimens for Early Relapse Multiple Myeloma
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Daratumumab/Lenalidomide/Dexamethasone (DRd)?
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Daratumumab/Lenalidomide/Dexamethasone (DRd)?
Are There Other Novel Approaches or Targeted Therapies for Early Relapse?
Are There Other Novel Approaches or Targeted Therapies for Early Relapse?
Can ARIs Be Combined with Radiation Therapy in High-Risk Localized Prostate Cancer?
Can ARIs Be Combined with Radiation Therapy in High-Risk Localized Prostate Cancer?
Opening Statements in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Opening Statements in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Closing Arguments in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Closing Arguments in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Expert Panel: What Is the Future of Early Intensification in Localized Prostate Cancer?
Expert Panel: What Is the Future of Early Intensification in Localized Prostate Cancer?
Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma
Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma
Defense: Argument for Single Agent ICI Adjuvant Treatment of Stage III Melanoma
Defense: Argument for Single Agent ICI Adjuvant Treatment of Stage III Melanoma